Nurix Therapeutics Reports Strong Phase 1b Data for BTK Degrader Bexobrutideg, Supporting Phase 3 & Roche Collaboration
Summary
Nurix Therapeutics announced updated positive clinical data for its lead BTK degrader, bexobrutideg, showing high response rates and a favorable safety profile in CLL/SLL patients, further validating its potential and supporting advancement to Phase 3.
Key Events
-
Updated Phase 1a/b Clinical Data
Nurix Therapeutics presented updated positive clinical data for its novel Bruton's tyrosine kinase (BTK) degrader, bexobrutideg (NX-5948), in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
-
High Objective Response Rates
The Phase 1a study in heavily pretreated patients showed an objective response rate (ORR) of 83.0% with a median progression-free survival of 22.1 months. New Phase 1b data in earlier-line cohorts demonstrated ORRs of 92.9% (BTKi-treated, BCL2i-naïve) and 84.2% (BTKi-naïve).
-
Favorable Safety Profile
Bexobrutideg was well tolerated across the Phase 1a/1b population, consistent with prior disclosures, with no dose-limiting toxicities or treatment-related Grade 5 adverse events reported.
-
Supports Phase 3 & Roche Collaboration
The updated data reinforces the potential for a broad Phase 3 monotherapy program and strengthens the rationale for exploring combination regimens, building on the recently announced global collaboration with Roche for bexobrutideg.
Analysis
This filing provides updated positive clinical data for Nurix's lead BTK degrader, bexobrutideg, which is critical as it directly validates the asset that recently secured a major global collaboration with Roche. The strong efficacy and safety profile in both heavily pretreated and earlier-line CLL/SLL patients significantly de-risks the drug's development and strengthens the rationale for advancing to a broad Phase 3 program. This positive data reinforces the investment thesis by demonstrating the drug's potential as a best-in-class therapy, crucial for a clinical-stage biopharmaceutical company.
At the time of this filing, NRIX was trading at $16.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.20 to $22.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.